New studies into retatrutide, a dual activator for GLP-1 and GIP receptors, are showing encouraging results in treating obesity and related second-type disease. Preclinical information suggest a distinct action https://shopretatrutidepeptide.com/2026/03/12/what-is-retatrutide-peptide/